SCHEMBL12008563

SCHEMBL12008563

Cc1ccc(/C=C2\SC(=S)N(CCC(=O)Nc3ccc(C(=O)O)c(O)c3)C2=O)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR35 Q9HC97 6/20 0.76
▸ PTPN12 Q05209 5/20 0.76
▸ PTPN22 Q9Y2R2 5/20 0.76
▸ KMT2A Q03164 12/20 0.75
▸ MEN1 O00255 10/20 0.75
▸ POLB P06746 6/20 0.72
▸ PTPN7 P35236 4/20 0.71
▸ PSMD14 O00487 2/20 0.71
▸ TDP1 Q9NUW8 3/20 0.70
▸ SAE1 Q9UBE0 2/20 0.70
▸ UBA2 Q9UBT2 2/20 0.70
▸ USP2 O75604 1/20 0.70
▸ NSD2 O96028 1/20 0.70
▸ ALPL P05186 1/20 0.70
▸ ALPI P09923 1/20 0.70
▸ ALPG P10696 1/20 0.70
▸ NPC1 O15118 1/20 0.69
▸ MAPT P10636 3/20 0.67
▸ MAPK1 P28482 2/20 0.67
▸ ALDH1A1 P00352 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12008621 0.93 KMT2A (0.75) GPR35PTPN12PTPN22KMT2AMEN1
SCHEMBL12008726 0.92 PTPN12 (0.90) GPR35PTPN12PTPN22KMT2AMEN1
SCHEMBL12008589 0.91 MEN1 (0.76) GPR35PTPN12PTPN22KMT2AMEN1
SCHEMBL12008606 0.91 PTPN12 (0.76) GPR35PTPN12PTPN22KMT2AMEN1
SCHEMBL12008716 0.91 NPC1 (0.83) GPR35PTPN12PTPN22KMT2AMEN1
SCHEMBL12008599 0.88 PTPN12 (0.91) GPR35PTPN12PTPN22KMT2AMEN1
SCHEMBL12692505 0.88 KMT2A (0.92) GPR35PTPN12PTPN22KMT2AMEN1
SCHEMBL12008709 0.86 PTPN12 (1.00) GPR35PTPN12PTPN22KMT2AMEN1
SCHEMBL12008780 0.86 KMT2A (0.83) GPR35PTPN12PTPN22KMT2AMEN1
SCHEMBL12692426 0.86 MEN1 (1.00) GPR35PTPN12KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF DASGUPTA RAMANUJ (US) 2017-02-23 — — US disclosed
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF DASGUPTA RAMANUJ (US) 2017-02-23 — — US disclosed
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 GPR35 302/4885PTPN12 226/4885PTPN22 374/4885
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof CTNNB1, CTNNA1, CTNNBL1 GPR35 299/4885PTPN12 457/4885PTPN22 534/4885
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 GPR35 299/4885PTPN12 457/4885PTPN22 534/4885
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 GPR35 299/4885PTPN12 457/4885PTPN22 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback